U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07004582) titled 'Lab Research Using Mini-tumors to Study Prostate Cancer Treatments' on May 15.
Brief Summary: For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with agg...